AnaptysBio, Inc (ANAB) shareholders
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Oleg Nodelman Joint filing with EcoR1 Capital, LLC (25.80%), EcoR1 Capital Fund Qualified, L.P. (24.20%) | 7,794,996 | 25.80% | 13D (active) amendment | Aug 14, 2024 |
| Tang Capital Management, LLC Joint filing with Tang Capital Partners, LP (7.30%), Kevin Tang (7.30%) | 1,950,609 | 7.30% | 13G (passive) amendment | Dec 31, 2023 |
| Alex Silverstein Joint filing with Sirenia Capital Management LP (6.70%) | 1,920,402 | 6.70% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 1,900,844 | 6.20% | 13G (passive) amendment | Mar 31, 2025 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (5.60%), Point72 Capital Advisors, Inc. (5.60%) | 1,691,372 | 5.60% | 13G (passive) | Feb 14, 2025 |
| Sirenia Capital Management LP Joint filing with Alex Silverstein (5.00%) | 1,491,959 | 5.00% | 13G (passive) amendment | Jun 30, 2026 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.10%), Israel A. Englander (5.10%) | 1,426,893 | 5.10% | 13G (passive) | Sep 16, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ANAB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 7,880,094 | 26.36% | $531.91M | −3,940,047 | 25.86% |
| BlackRock, Inc. | 1,844,049 | 6.17% | $124.47M | −678,023 | 0.00% |
| Tang Capital Management LLC | 1,330,879 | 4.45% | $89.83M | −665,440 | 4.08% |
| State Street Corp | 1,286,194 | 4.30% | $86.82M | −202,474 | 0.00% |
| Vanguard Capital Management LLC | 906,233 | 3.03% | $61.17M | −373,494 | 0.00% |
| Affinity Asset Advisors, LLC | 826,109 | 2.76% | $55.76M | −583,891 | 2.52% |
| Sanofi | 821,917 | 2.75% | $55.48M | −410,959 | 10.39% |
| Millennium Management LLC | 807,316 | 2.70% | $54.49M | +93,958 | 0.02% |
| Woodline Partners LP | 717,014 | 2.40% | $48.40M | +200,630 | 0.15% |
| 683 Capital Management, LLC | 660,000 | 2.21% | $44.55M | −277,500 | 2.19% |
| Geode Capital Management, LLC | 637,873 | 2.13% | $43.06M | −142,489 | 0.00% |
| Palo Alto Investors LP | 603,489 | 2.02% | $40.74M | −353,753 | 5.63% |
| Goldman Sachs Group Inc | 584,070 | 1.95% | $39.42M | +84,955 | 0.00% |
| First Light Asset Management, LLC | 582,004 | 1.95% | $39.29M | −266,143 | 2.39% |
| D. E. Shaw & Co., Inc. | 539,666 | 1.81% | $36.43M | −329,278 | 0.02% |
| Vanguard Portfolio Management LLC | 527,858 | 1.77% | $35.63M | −251,947 | 0.00% |
| Apis Capital Advisors, LLC | 497,000 | 1.66% | $33.55M | +140,000 | 3.27% |
| Sofinnova Investments, Inc. | 493,536 | 1.65% | $33.31M | +121,156 | 1.72% |
| Arrowstreet Capital, Limited Partnership | 488,651 | 1.63% | $32.98M | −249,529 | 0.01% |
| Nuveen, LLC | 420,664 | 1.41% | $28.39M | −53,434 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 213 | 30M | 100.0% | 46 / 23 | 144 / 37 | 2M | 15M |
| Q1 2026 | 208 | 42M | 100.0% | 51 / 59 | 70 / 20 | 8M | 7M |
| Q4 2025 | 179 | 44M | 100.0% | 37 / 51 | 64 / 24 | 5M | 8M |
| Q3 2025 | 166 | 48M | 100.0% | 35 / 43 | 59 / 15 | 7M | 14M |
| Q2 2025 | 147 | 55M | 100.0% | 27 / 46 | 54 / 31 | 8M | 13M |
| Q1 2025 | 153 | 60M | 100.0% | 45 / 44 | 43 / 26 | 20M | 13M |
| Q4 2024 | 135 | 53M | 100.0% | 27 / 50 | 35 / 52 | 12M | 10M |
| Q3 2024 | 160 | 50M | 100.0% | 38 / 61 | 31 / 11 | 12M | 3M |
| Q2 2024 | 135 | 45M | 100.0% | 26 / 43 | 45 / 23 | 10M | 11M |
| Q1 2024 | 133 | 46M | 100.0% | 26 / 41 | 40 / 12 | 6M | 6M |
| Q4 2023 | 119 | 46M | 100.0% | 16 / 32 | 43 / 13 | 5M | 5M |
| Q3 2023 | 116 | 46M | 100.0% | 14 / 34 | 38 / 14 | 7M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
212 funds held ANAB in Q2 2026, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ANAB | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 786,627 | 2.63% | $53.10M | 0.49% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 648,146 | 2.17% | $43.75M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 514,945 | 1.72% | $34.76M | 0.04% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 263,840 | 0.88% | $14.08M | 0.35% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 237,032 | 0.79% | $16.00M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 215,873 | 0.72% | $11.52M | 0.03% | Jul 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 210,000 | 0.70% | $11.21M | 0.39% | Jul 31, 2026 |
| iShares Biotechnology ETF | 193,528 | 0.65% | $13.06M | 0.14% | Jun 30, 2026 |
| Victory Science & Technology Fund | 187,893 | 0.63% | $10.03M | 0.67% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 185,548 | 0.62% | $12.52M | 0.08% | Jun 30, 2026 |
| Burney U.S. Equity Select ETF | 148,943 | 0.50% | $7.95M | 1.18% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 131,265 | 0.44% | $8.86M | 0.07% | Jun 30, 2026 |
| First Trust Small Cap Growth AlphaDEX Fund | 130,011 | 0.43% | $6.94M | 0.53% | Jul 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 127,704 | 0.43% | $6.81M | 0.30% | Jul 31, 2026 |
| Burney U.S. Factor Rotation ETF | 123,969 | 0.41% | $6.61M | 1.14% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel Faga | President, CEO, Director | 510,564 | 1.71% | Aug 7, 2026 |
| Paul F. Lizzul | Chief Medical Officer | 42,088 | 0.14% | Aug 7, 2026 |
| Christopher M. Murphy | Chief Financial Officer | – | – | May 13, 2026 |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | 12,835 | 0.04% | Feb 13, 2026 |
| Dennis Mulroy | CHIEF FINANCIAL OFFICER | 21,852 | 0.07% | Jan 9, 2026 |
| Hollings Renton | Director | 10,995 | 0.04% | Oct 2, 2026 |
| John A. Orwin | Director | 17,995 | 0.06% | Sep 17, 2026 |
| John P. Schmid | Director | 37,652 | 0.13% | Jun 17, 2026 |
| Owen Hughes | Director | – | – | May 13, 2026 |
| Susannah Gray | Director | – | – | Apr 29, 2026 |
| Magda Marquet | Director | 20,930 | 0.07% | Jan 16, 2026 |
| J. Anthony Ware | Director | 9,630 | 0.03% | Jan 8, 2026 |
| Rita Jain | Director | 11,864 | 0.04% | Jan 8, 2026 |
| Dennis M. Fenton | Director | 4,965 | 0.02% | Jan 8, 2026 |
| EcoR1 Capital, LLC | Director, 10% owner | 7,880,094 | 26.36% | Jan 2, 2025 |
| Oleg Nodelman | Director, 10% owner | 7,520,424 | 25.16% | Jan 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Hollings Renton Director | Oct 1, 2026 | Sale(10b5-1 plan) | −5,000 | $49.87 | $249.37K | 10,995 |
| Hollings Renton Director | Oct 1, 2026 | Option exercise | +5,000 | $18.03 | $90.15K | 15,995 |
| John A. Orwin Director | Sep 15, 2026 | Option exercise | +1,300 | – | – | 17,995 |
| John A. Orwin Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 16,695 |
| John P. Schmid Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 37,652 |
| Hollings Renton Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 10,995 |
| John P. Schmid Director | Mar 30, 2026 | Sale | −522 | $57.40 | $29.96K | 31,622 |
| John P. Schmid Director | Mar 30, 2026 | Sale | −7,527 | $56.70 | $426.78K | 32,144 |
| John P. Schmid Director | Mar 30, 2026 | Sale | −12,596 | $55.71 | $701.72K | 39,671 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −2,570 | $57.91 | $148.83K | 510,564 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −510 | $56.61 | $28.87K | 513,134 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −3,662 | $58.62 | $214.67K | 506,902 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −490 | $59.62 | $29.21K | 506,412 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −550 | $60.63 | $33.35K | 505,862 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −1,012 | $62.15 | $62.90K | 504,850 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −2,592 | $63.35 | $164.20K | 502,258 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −3,155 | $64.19 | $202.52K | 499,103 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −3,038 | $65.20 | $198.08K | 496,065 |
| Daniel Faga President, CEO, Director | Mar 27, 2026 | Sale | −100 | $65.99 | $6.60K | 495,965 |
| Daniel Faga President, CEO, Director | Mar 25, 2026 | Award | +34,300 | – | – | 513,644 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Feb 11, 2026 | Sale(10b5-1 plan) | −10,000 | $54.00 | $540.00K | 12,835 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Feb 11, 2026 | Option exercise | +10,000 | $29.70 | $297.00K | 22,835 |
| Magda Marquet Director | Jan 15, 2026 | Option exercise | +11,000 | $26.11 | $287.21K | 20,930 |
| Magda Marquet Director | Jan 15, 2026 | Sale | −1,710 | $48.85 | $83.53K | 9,930 |
| Magda Marquet Director | Jan 15, 2026 | Sale | −9,290 | $48.12 | $447.03K | 11,640 |
| Daniel Faga President, CEO, Director | Jan 8, 2026 | Sale | −14,281 | $44.71 | $638.50K | 479,344 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 8, 2026 | Sale | −2,515 | $44.71 | $112.45K | 21,852 |
| Paul F. Lizzul Chief Medical Officer | Jan 8, 2026 | Sale | −3,650 | $44.71 | $163.19K | 42,088 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 8, 2026 | Sale | −2,210 | $44.71 | $98.81K | 12,835 |
| Daniel Faga President, CEO, Director | Jan 7, 2026 | Option exercise | +26,838 | – | – | 493,625 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 7, 2026 | Option exercise | +6,700 | – | – | 24,367 |
| Paul F. Lizzul Chief Medical Officer | Jan 7, 2026 | Option exercise | +8,525 | – | – | 45,738 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 7, 2026 | Option exercise | +5,888 | – | – | 15,045 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 7, 2026 | Sale(10b5-1 plan) | −1,841 | $46.13 | $84.93K | 9,657 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 7, 2026 | Sale(10b5-1 plan) | −500 | $47.23 | $23.62K | 9,157 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 7, 2026 | Sale(10b5-1 plan) | −5,281 | $45.38 | $239.65K | 11,498 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 7, 2026 | Sale(10b5-1 plan) | −2,017 | $45.11 | $90.99K | 16,779 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 7, 2026 | Sale | −1,908 | $45.11 | $86.07K | 17,667 |
| Paul F. Lizzul Chief Medical Officer | Jan 7, 2026 | Sale | −2,235 | $45.11 | $100.82K | 37,213 |
| Daniel Faga President, CEO, Director | Jan 7, 2026 | Sale | −9,202 | $45.11 | $415.10K | 466,787 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 6, 2026 | Option exercise | +5,545 | – | – | 18,796 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 6, 2026 | Option exercise | +5,245 | – | – | 19,575 |
| Paul F. Lizzul Chief Medical Officer | Jan 6, 2026 | Option exercise | +6,145 | – | – | 39,448 |
| Daniel Faga President, CEO, Director | Jan 6, 2026 | Option exercise | +17,850 | – | – | 475,989 |
| Paul F. Lizzul Chief Medical Officer | Jan 5, 2026 | Sale | −4,219 | $43.26 | $182.51K | 33,303 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 5, 2026 | Sale | −2,983 | $43.26 | $129.04K | 13,251 |
| Daniel Faga President, CEO, Director | Jan 5, 2026 | Sale | −15,309 | $43.26 | $662.27K | 458,139 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 5, 2026 | Sale | −3,363 | $43.26 | $145.48K | 14,330 |
| Paul F. Lizzul Chief Medical Officer | Jan 3, 2026 | Option exercise | +10,555 | – | – | 37,522 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Jan 3, 2026 | Option exercise | +7,287 | – | – | 16,234 |
| Daniel Faga President, CEO, Director | Jan 3, 2026 | Option exercise | +34,677 | – | – | 473,448 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Jan 3, 2026 | Option exercise | +8,292 | – | – | 17,693 |
| J. Anthony Ware Director | Dec 23, 2025 | Sale | −3,900 | $49.58 | $193.36K | 9,630 |
| John P. Schmid Director | Dec 23, 2025 | Other | −11,068 | $51.00 | $564.47K | 0 |
| Paul F. Lizzul Chief Medical Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −1,500 | $50.00 | $75.00K | 26,967 |
| Paul F. Lizzul Chief Medical Officer | Dec 22, 2025 | Option exercise | +1,500 | $18.50 | $27.75K | 28,467 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Dec 22, 2025 | Option exercise | +10,000 | $14.02 | $140.20K | 18,947 |
| Eric J. Loumeau CHIEF LEGAL OFFICER | Dec 22, 2025 | Sale(10b5-1 plan) | −10,000 | $51.00 | $510.00K | 8,947 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Dec 22, 2025 | Option exercise | +10,000 | $20.16 | $201.60K | 19,401 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER | Dec 22, 2025 | Sale(10b5-1 plan) | −10,000 | $50.00 | $500.00K | 9,401 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AnaptysBio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,739 shares on Oct 5, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Hollings Renton Director | Oct 1, 2026 | 5,000 | $249.37K | Oct 1, 2026 | Stock Option Exercise |
| J. Anthony Ware Director | Jul 13, 2026 | 10,694 | $718.33K | Jul 13, 2026 | Stock Option Exercise |
| J. Anthony Ware Director | Jun 30, 2026 | 6,030 | $408.77K | Jun 30, 2026 | Restricted Stock |
| Dennis Mulroy Officer | Jun 29, 2026 | 9,476 | $601.21K | Jun 29, 2026 | Stock Option Exercise |
| Dennis Mulroy Officer | Jun 26, 2026 | 10,000 | $608.18K | Jun 26, 2026 | Stock Option Exercise |
| Dennis Mulroy Officer | Jun 17, 2026 | 850 | $51.00K | Jun 17, 2026 | Stock Option Exercise |
| Dennis Mulroy Officer | Jun 16, 2026 | 1,265 | $75.90K | Jun 16, 2026 | Stock Option Exercise |
| Dennis Mulroy Officer | Jun 15, 2026 | 20,000 | $1.15M | Jun 15, 2026 | Stock Option Exercise |
| Dennis Mulroy Officer | Jun 12, 2026 | 20,000 | $1.11M | Jun 12, 2026 | Stock Option Exercise |
| Dennis Mulroy Officer | Jun 11, 2026 | 35,000 | $1.85M | Jun 11, 2026 | Stock Option Exercise |
| Dennis Mulroy Officer | Jun 10, 2026 | 20,000 | $1.05M | Jun 10, 2026 | Stock Option Exercise |
| Dennis Mulroy Officer | Jun 9, 2026 | 20,000 | $1.03M | Jun 9, 2026 | Stock Option Exercise |
| Dennis Mulroy Officer | Jun 8, 2026 | 21,987 | $1.12M | Jun 8, 2026 | Restricted Stock |
| Dennis Mulroy Officer | Jun 5, 2026 | 22,491 | $1.15M | Jun 5, 2026 | Stock Option Exercise |
| Dennis Mulroy Officer | Jun 5, 2026 | 20,000 | $1.04M | Jun 4, 2026 | Stock Option Exercise |
See a number that looks wrong?